Anterios Inc. closed an $8.5 million corporate financing.
Esperion Therapeutics Inc. pulled down $33 million in a preferred stock financing.
Genticel SA raised $23.6 million in a Series C round led by Wellington Partners.
GW Pharmaceuticals plc set the terms for its proposed U.S. IPO aiming to raise about $40 million.
iBio Inc. priced a public offering of 8.925 million units at 48 cents each, raising $4.28 million.
Insys Therapeutics Inc. plans to raise $68 million in an IPO of 4 million shares priced at $16 to $18.
Ohr Pharmaceutical Inc. raised about $5.05 million through the exercise of Series B warrants.
Radius Health Inc. received $43 million in a financing led by F2 Biosciences III L.P.
ARCA biopharma Inc. entered an agreement with Medtronic Inc. for a Phase IIb/III trial.
BIND Therapeutics Inc. signed a deal with AstraZeneca plc to develop an Accurin therapeutic based on a molecular-targeted kinase inhibitor.
BioTime Inc. entered a license agreement with the UCLA for technology related to the treatment of stroke.
Cerecor Inc. acquired the rights to an NMDA antagonist for development in depression from Merck & Co. Inc.
DSM Pharmaceutical Products signed an agreement with DecImmune Therapeutics Inc., covering the development of its monoclonal antibody program.
Horizon Discovery Ltd. has inked a deal with AstraZeneca plc for its genome-editing technology.
Kymab Ltd. signed a deal with Novo Nordisk A/S covering its transgenic mouse antibody platform.
OPKO Health Inc. and Prolor Biotech Inc. are seeking to merge in an all-stock transaction valued at about $480 million.
. . . And More
Elan Corp. plc said its board has determined that Royalty Pharma's offer to acquire the company for $11.25 or less per share substantially undervalues the company.
The Patient-Centered Outcomes Research Institute is providing up to $68 million to support development of a National Patient-Centered Clinical Research Network.
OvaScience's common stock was approved for listing on Nasdaq under the ticker "OVAS."
TNI BioTech Inc. filed its Form 10 with the SEC to become a fully reporting public company.